Dr. Arvind Chaudhry, MD

Dr. Chaudhry practices at Medical Oncology Associates, P.S. in Spokane, Washington.

Dr. Chaudhry's NPI, 1750336236, was assigned on May 23, 2006. Dr. Chaudhry holds Washington license MD00037930.

Dr. Chaudhry's primary practice is Medical Oncology Associates, P.S., at 6001 N Mayfair St, Spokane, WA 99208 in Spokane County. The practice phone is (509) 462-2273.

Dr. Chaudhry's primary practice is Medical Oncology Associates, P.S. in Spokane, Washington. Dr. Chaudhry is also affiliated with Prov Sacred Hrt Med Ctr & Childs Hosp. The medical group on file is Medical Oncology Associates. Dmand AI also links Dr. Chaudhry to 4 more hospitals, 1 group practice or clinic and 1 hospice, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Chaudhry practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Chaudhry's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Chaudhry is licensed in Washington.

CMS data shows 101,047 Medicare services from Dr. Chaudhry across 49 procedure codes in 2024, for 972 Medicare patients. Medicare paid $2,429,504 for them.

CMS counts 972 Medicare patients who saw Dr. Chaudhry in 2024. The largest group is 75 to 84, with 423 patients. 67% of them have high blood pressure, and 62% have high cholesterol. 8% are also on Medicaid. Their average risk score is 1.79, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Chaudhry's median patient age at 72, with 55% women.

In 2024, Dr. Chaudhry wrote 2,083 Medicare Part D claims for 321 patients. 65% of them were for generic drugs. CMS names the drug for 1,833 of them, across 47 drugs with 11 or more claims each, at $7,795,143 in total drug cost. In 2023, CMS named 1,503 claims across 42 drugs.

Dr. Chaudhry accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Chaudhry as offering telehealth.

Dmand AI links 7 papers to Dr. Chaudhry, published from 2013 to 2024. 2015 was the busiest year, with 2. The most frequent topics are Protein Kinase Inhibitors, Adenoviridae and Antibodies, Monoclonal, Humanized. Dr. Chaudhry has published most often in Cancer Immunol Immunother. Dr. Chaudhry's most frequent co-authors are John McEvoy Burke, MD, Aileen Cleary Cohen, MD and Ian Winchester Flinn, MD.

Dmand AI links Dr. Chaudhry to 12 clinical trials, 3 of them phase 3 studies. Conditions studied include Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung and Carcinoma, Transitional Cell. Arcus Biosciences, Inc. sponsors the most, 4. Open Payments lists research payments to Dr. Chaudhry that name 3 trials.

CMS Open Payments shows 2,521 general payments to Dr. Chaudhry from 117 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 36% of the total. Bayer HealthCare Pharmaceuticals Inc. paid the most, $46,156. It also lists 8 research payments totaling $19,422 from 2019 to 2025, naming 3 clinical trials.